Objectives

At the conclusion of this session, participants will be able to:

•Review major new evidence as it related to lipid management in 2023

•Overview of the use of apoB, non-HDL-C and lipoprotein(a) in clinical care

•Briefly review new therapies in development for dyslipidemia

Presentations by George Thanassoulis

• Mon-04 from 08:20 - 10:35 in room
  Plenary - 1
  The CCS dyslipidemia guidelines - What's new and what's important?
• Mon-04 from 11:00 - 12:00 in room
  A-08 - Applying the 2021 CCS Dyslipidemia Guidelines in Clinical Practice - George Thanassoulis
  Applying the 2021 CCS Dyslipidemia Guidelines in Clinical Practice